USFDA completes inspection at Strides Pharma Science's Singapore facility

09 Aug 2022 Evaluate

Strides Pharma Science’s formulation facility at Singapore underwent a United States Food & Drug Administration (USFDA) inspection that ended on August 8, 2022. The inspection was completed successfully with Zero 483 observations.

US is one of the key focus markets for Strides and the company has given a growth outlook of $250m in FY23 for the US business. The company has set a target to launch 20 new products every year in the US. The company has 279 cumulative ANDA filings (including recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 259 ANDAs have been approved and 20 are pending approval. The company has a diversified manufacturing base with 5 USFDA approved facilities which are capable of catering to multiple dosage formats including niche capabilities in controlled Substances, Hormones, Nasal Sprays, Gels, Modified Release products, Liquids.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

793.30 -2.90 (-0.36%)
27-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1636.05
Dr. Reddys Lab 1240.00
Cipla 1313.20
Zydus Lifesciences 895.85
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×